Silence Therapeutics Gmbh

David Anthony Rider

Christian Frauendorf

Lucas Bethge

Judith Hauptmann

Adrien Weingärtner

Sibylle Dames

Steffen Schubert

Stephan Tenbaum

Adrien Weingartner

Adrien Weingaertner

Adrien WEINGÄERTNER

The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression, preferably for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated levels of Lp(a) particles.

Nucleic acids for inhibiting expression of LPA in a cell

The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated of Lp(a)-containing particles.

Growing community of inventors

Berlin, Germany

David Anthony Rider